WHO ICTRP trial
Study on biomarkers of chemotherapy combined with immunotherapy for esophageal…
ChiCTR2500104234 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2500104234 |
|---|---|
| Public title | Study on biomarkers of chemotherapy combined with immunotherapy for esophageal squamous cell carcinoma |
| Scientific title | Study on biomarkers of albumin paclitaxel, platinum based chemotherapy combined with PD-1 monoclonal antibody to treat esophageal squamous cell carcinoma |
| Primary sponsor | Beijing Cancer Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Observational study |
| Countries | China |
| Conditions | esophageal squamous cell carcinoma |
| Interventions | Exposed group:None |
| Registration date | Jun 13, 2025 |
| Target size | Exposed group:50 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: